Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles

International Psychogeriatrics

Volumn 27, Issue 3, 2015, Pages 429-437

  Park, Moon Ho ^a   Han, Changsu ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

biomarkers; mild cognitive impairment (MCI); misdiagnosis; reversion

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING; COGNITION; CONVALESCENCE; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; FALSE POSITIVE RESULT; FEMALE; FUNCTIONAL ACTIVITIES QUESTIONNAIRE; GENETIC SCREENING; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; QUESTIONNAIRE; REY AUDITORY VERBAL LEARNING TEST; WHITE MATTER; BRAIN; COGNITION DISORDERS; DEMENTIA; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DEMENTIA; DIAGNOSTIC ERRORS; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS;

EID: 84922223919     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610214002129     Document Type: Article

References (30)

1. ADNI. (2013a). ADNI prcedures, protocols and grants. In Alzheimer's Disease Neuroimaging Initiative. Available at: http://www.adni-info.org/Scientists/ADNIStudyProcedures.aspx; last accessed 17 November 2013.
2. ADNI. (2013b). Download study data. In Alzheimer' Disease Neuroimaging Initiative. Available at: https://ida.loni. usc.edu/pages/access/studyData.jsp; last accessed 17 November 2013.
3. Albert, M. S. et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 7, 270-279. doi:10.1016/j.jalz.2011.03.008.
4. Busse, A., Hensel, A., Guhne, U., Angermeyer, M. C. and Riedel-Heller, S. G. (2006). Mild cognitive impairment: long-term course of four clinical subtypes. Neurology, 67, 2176-2185. doi:10.1212/01.wnl.0000249117.23318.e1.
5. de Jager, C. A. and Budge, M. M. (2005). Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. Neurocase, 11, 72-79. doi:10.1080/13554790490896820.
6. Edmonds, E. C. et al. (2014). Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimer's and Dementia. Epublished ahead of print, doi:10.1016/j.jalz.2014.03.005.
7. Fisk, J. D., Merry, H. R. and Rockwood, K. (2003). Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology, 61, 1179-1184.
8. Gallassi, R. et al. (2010). Are subjective cognitive complaints a risk factor for dementia? Neurological Science, 31, 327-336. doi:10.1007/s10072-010-0224-6.
9. Ganguli, M., Dodge, H. H., Shen, C. and DeKosky, S. T. (2004). Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology, 63, 115-121.
10. Ganguli, M. et al. (2011). Outcomes of mild cognitive impairment by definition: a population study. Archives of Neurology, 68, 761-767. doi:10.1001/archneurol.2011.101.
11. Han, J. W. et al. (2012). Predictive validity and diagnostic stability of mild cognitive impairment subtypes. Alzheimer's and Dementia, 8, 553-559. doi:10.1016/j.jalz.2011.08.007.
12. Jack, C. R., Jr. Jack et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, 9, 119-128. doi:10.1016/S1474-4422(09)70299-6.
13. Klekociuk, S. Z., Summers, J. J., Vickers, J. C. and Summers, M. J. (2014). Reducing false positive diagnoses in mild cognitive impairment: the importance of comprehensive neuropsychological assessment. European Journal of Neurololgy, 21, 1330-e1383. doi:10.1111/ene.12488.
14. Koepsell, T. D. and Monsell, S. E. (2012). Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology, 79, 1591-1598. doi:10.1212/WNL.0b013e31826e26b7.
15. Larrieu, S. et al. (2002). Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology, 59, 1594-1599.
16. Lezak, M. D., Howieson, D. B., Bigler, E. D. and Tranel, D. (2012). Neuropsychological Assessment. Oxford, UK: Oxford University Press.
17. Lopez, O. L. et al. (2012). Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology, 79, 1599-1606. doi:10.1212/WNL.0b013e31826e25f0.
18. Mitchell, A. J. and Shiri-Feshki, M. (2009). Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica, 119, 252-265. doi:10.1111/j.1600-0447.2008.01326.x.
19. Mormino, E. C. et al. (2009). Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain, 132, 1310-1323. doi:10.1093/brain/awn320.
20. Nordlund, A., Rolstad, S., Klang, O., Edman, A., Hansen, S. and Wallin, A. (2010). Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. Journal of Neurology, Neurosurgery, and Psychiatry, 81, 541-546. doi:10.1136/jnnp.2008.171066.
21. Olazaran, J. et al. (2011). Mild cognitive impairment and dementia in primary care: the value of medical history. Family Practice, 28, 385-392. doi:10.1093/fampra/cmr005.
22. Petersen, R. C. (2011). Clinical practice. Mild cognitive impairment. New England Journal of Medicine, 364, 2227-2234. doi:10.1056/NEJMcp0910237.
23. Petersen, R. C. et al. (2010). Alzheimer's Disease neuroimaging initiative (ADNI): clinical characterization. Neurology, 74, 201-209. doi:10.
24. Reitz, C., Brayne, C. and Mayeux, R. (2011). Epidemiology of Alzheimer's disease. Nature Reviews. Neurology, 7, 137-152. doi:10.1038/nrneurol.2011.2.
25. Roberts, R. O. et al. (2014). Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology, 82, 317-325. doi:10.1212/WNL.0000000000000055.
26. Rosen, C., Hansson, O., Blennow, K. and Zetterberg, H. (2013). Fluid biomarkers in Alzheimer's disease-current concepts. Molecular Neurodegeneration, 8, 20. doi:10.1186/1750-1326-8-20.
27. Shaw, L. M. et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 65, 403-413. doi:10.1002/ana.21610.
28. Sperling, R. A. et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7, 280-292. doi:10.1016/j.jalz.2011.03.003.
29. Tyas, S. L. et al. (2007). Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. American Journal of Epidemiology, 165, 1231-1238. doi:10.1093/aje/kwm085.
30. Zonderman, A. B. and Dore, G. A. (2014). Risk of dementia after fluctuating mild cognitive impairment: when the yo-yoing stops. Neurology, 82, 290-291. doi:10.1212/WNL.0000000000000065.